A Singular Vision

Singular Vision

Relentless pursuit of transformative therapies targeting FcRn, a central mediator in autoimmune responses.

Focused Execution

Focused Execution

Rapid clinical advancement across multiple indications for our lead investigational candidate SYNT001.

Vast Reach

Vast Reach

FcRn plays a central role across a wide swath of autoimmune diseases affecting millions of people worldwide.

NEWS & PROGRESS

SEPTEMBER 12, 2018

Syntimmune Announces FDA Orphan Drug Designation for SYNT001 in Treatment of Pemphigus

LATEST TWEET

@syntimmune | SEPTEMBER 13, 2018

We’re a dynamic company built on the foundational values of respect, trust, integrity, responsibility and teamwork.… https://t.co/oAkz4bcVso